SPI

SPI handeln
18.551,09 PKT +155,85 PKT +0,85 %
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

WKN 998750

ISIN CH0009987501


Analysen zu SPI-Werten

Datum Rating Analyst
15.07.11 Holcim buy Société Générale Group S.A. (SG)
15.07.11 ABB (Asea Brown Boveri) sell UniCredit Research
14.07.11 UBS halten Independent Research GmbH
14.07.11 Givaudan hold UniCredit Research
14.07.11 Clariant buy UniCredit Research
14.07.11 ABB (Asea Brown Boveri) buy Citigroup Corp.
14.07.11 Roche hold Citigroup Corp.
14.07.11 Sulzer buy Vontobel Research
14.07.11 Givaudan neutral Macquarie Research
14.07.11 Givaudan hold Vontobel Research
14.07.11 Partners Group hold Vontobel Research
14.07.11 Barry Callebaut hold Vontobel Research
13.07.11 Novartis buy Citigroup Corp.
13.07.11 Holcim overweight J.P. Morgan Cazenove
13.07.11 Lonza hold Citigroup Corp.
12.07.11 Nestlé halten Independent Research GmbH
12.07.11 Kühne + Nagel International buy Nomura
12.07.11 ABB (Asea Brown Boveri) hold Société Générale Group S.A. (SG)
12.07.11 Swatch (I) buy Vontobel Research
12.07.11 Nestlé outperform Sanford C. Bernstein and Co., Inc.
12.07.11 Nestlé buy Vontobel Research
12.07.11 Holcim buy Vontobel Research
11.07.11 Clariant reduce Nomura
11.07.11 Nestlé hold Citigroup Corp.
11.07.11 Lonza hold Citigroup Corp.
11.07.11 Barry Callebaut hold Vontobel Research
11.07.11 Swatch (I) buy Citigroup Corp.
11.07.11 Novartis buy Vontobel Research
11.07.11 Nestlé buy Vontobel Research
11.07.11 Lonza hold Vontobel Research
11.07.11 Peach Property Group buy SRC Research GmbH
11.07.11 Lonza kaufen Fuchsbriefe
08.07.11 Sika buy Vontobel Research
08.07.11 Implenia hold Vontobel Research
08.07.11 Novartis buy Vontobel Research
07.07.11 Clariant kaufen Vontobel Research
07.07.11 Novartis kaufen Independent Research GmbH
07.07.11 Givaudan neutral Banc of America Securities-Merrill Lynch
06.07.11 Nestlé halten Independent Research GmbH
06.07.11 Novartis overweight J.P. Morgan Cazenove